PTC Therapeutics (PTCT)
Develops rare-disease medicines spanning PKU, DMD, gene therapy, and RNA-splicing programs.
$65.96
After hours+0.01 (+0.02%)
At close$65.95(+1.06%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 121.41% | 101.33M shares | |
|---|---|---|---|
| 392 holders · as of Jun 30, 2026 | |||
| Insiders | 6.55% | 5.47M shares | |
| 19 holders · as of Sep 18, 2026 | |||
| Strategic holders | 8.62% | 7.19M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 136.58% | ||
83.46M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 136.58%; nothing is left for Other.
13F, as of Jun 30, 2026
392 holders · 101.33M shares · 75 new positions · 217 increased · 115 reduced · 46 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.96M | 16.73% | +1.02M | Aug 7, 2026 |
| RTW Investments, LP | 7.75M | 9.28% | 0 | Aug 14, 2026 |
| Jupiter Topco LLC | 7.24M | 8.67% | +7.24Mnew | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 4.93M | 5.90% | +123.5K | Aug 13, 2026 |
| State Street Corp | 4.60M | 5.51% | +252.4K | Aug 7, 2026 |
| Wellington Management Group LLP | 4.13M | 4.95% | +185.7K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 3.74M | 4.48% | +62.9K | Aug 13, 2026 |
| Geode Capital Management, LLC | 2.21M | 2.64% | −2.6K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.80% | 11.90M | 13G | Dec 4, 2025 |
| Janus Henderson Group PLC | 8.70% | 7.19M | 13G | May 15, 2026 |
| Armistice Capital, LLC | 6.86% | 5.43M | 13G | May 15, 2025 |
| Vanguard Portfolio Management | 5.88% | 4.87M | 13G | Apr 29, 2026 |
| State Street Corporation | 5.20% | 4.21M | 13G | Feb 9, 2026 |
| Vanguard Capital Management | 5.17% | 4.28M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 17, 2026 | Michael Schmertzlerdirector | Sale · 2 lots | 10,000 | $67.85 | 1,296,594 |
| Sep 16, 2026 | Michael Schmertzlerdirector | Sale · 2 lots | 10,000 | $67.12 | 1,306,594 |
| Sep 10, 2026 | Michael Schmertzlerdirector | Sale | 10,000 | $67.34 | 1,316,594 |
| Sep 9, 2026 | Michael Schmertzlerdirector | Sale · 2 lots | 10,000 | $67.84 | 1,326,594 |
| Aug 27, 2026 | Michael Schmertzlerdirector | Sale · 2 lots | 12,500 | $71.58 | 1,336,594 |
| Aug 26, 2026 | Michael Schmertzlerdirector | Sale · 2 lots | 12,500 | $72.94 | 1,349,094 |
| Aug 20, 2026 | Michael Schmertzlerdirector | Sale · 3 lots | 12,500 | $71.11 | 1,361,594 |
| Aug 19, 2026 | Michael Schmertzlerdirector | Sale · 2 lots | 12,500 | $73.32 | 1,374,094 |
| Aug 17, 2026 | Mark Elliott Bouldingofficer: EXEC. VP AND CLO | Sale · 2 lots | 2,813 | $72.57 | 105,272 |
| Aug 4, 2026 | Matthew B. Kleindirector, officer: CHIEF EXECUTIVE OFFICER | Sale | 10,292 | $68.57 | 383,868 |
House and Senate disclosures
Not reported.